Sattva S. Neelapu

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

82h-index42.0kcitations868works3.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(413), CAR-T cell therapy research(388), Chronic Lymphocytic Leukemia Research(166), Immune Cell Function and Interaction(90), Immunotherapy and Immune Responses(89)

Publications868 total

From Autoinflammation to Oncogenesis: A 17-Year Evolution of Schnitzler Syndrome with Marginal Zone Lymphoma, Injection-Site Amyloidosis, and Metastatic Melanoma

International Journal of Cancer Care and Delivery·2025

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Blood·2025

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood·2025Open Access

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood·2025

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Blood·2025Open Access

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood·2025Open Access

KIR3DL2-directed CAR T cell therapy for T cell malignancies

Blood·2025

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Blood·2025Open Access

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Blood·2025

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Blood·2025Open Access

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Blood·2025

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Blood·2025

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood·2025Open Access

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Blood·2025Open Access

Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy

Blood·2025Open Access

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Blood·2025Open Access

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Blood·2025Open Access

A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies

Blood·2025Open Access

Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming

Blood·2025

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Blood·2025

page 1 of 44Next →

Frequent Co-authors

Frederick L. Locke(15), Jason R. Westin(13), Luis Fayad(12), David B. Miklos(11), Yi Lin(11), Felipe Samaniego(11), Caron A. Jacobson(10), Olalekan O. Oluwole(10), Loretta J. Nastoupil(10), Larry W. Kwak(10), Lazaros J. Lekakis(9), Armin Ghobadi(9), John M. Rossi(9), Michael Wang(9), Javier Muñoz(8), Michelle A. Fanale(8), Julio C. Chávez(7), Patrick M. Reagan(7), Adrian Bot(7), William Y. Go(7)